Literature DB >> 26513427

Psychological therapies for the management of chronic neuropathic pain in adults.

Christopher Eccleston1, Leslie Hearn, Amanda C de C Williams.   

Abstract

BACKGROUND: Neuropathic pain is thought to arise from damage to the somatosensory nervous system. Its prevalence is increasing in line with many chronic disorders such as diabetes. All treatments have limited effectiveness. Given the evidence regarding psychological treatment for distress and disability in people with various chronic pain conditions, we were interested to investigate whether psychological treatments have any effects for those with chronic neuropathic pain.
OBJECTIVES: To assess the effects of psychological treatments on pain experience, disability, mood, and health-care use in adults with chronic neuropathic pain. SEARCH
METHODS: We searched for randomised controlled trials (RCTs) published in any language in the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, EMBASE, and PsycINFO, from database inception to March 2015. SELECTION CRITERIA: Full publications of RCTs on psychological interventions for neuropathic pain. Trials had to have lasted at least three months, had at least 20 participants in each arm at the end of treatment, and compared a psychological intervention with any active or inactive intervention. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by Cochrane. MAIN
RESULTS: Two small studies (enrolling a total of 105 participants) met the inclusion criteria. One was a standard cognitive behavioural treatment (CBT) programme for 61 people with pain from spinal cord injury, followed up for three months, and compared with a waiting list. The other was weekly group psychotherapy for 44 people with burning mouth syndrome, compared with a daily placebo tablet. The overall risk of bias was high in both trials.The CBT study assessed participants for pain, disability, mood, and quality of life, with improvement in treatment and control groups. However, there was no more improvement in the treatment group than in the control for any outcome, either post-treatment or at follow-up. The group psychotherapy study only assessed pain, classifying participants by pain severity. There is a lack of evidence on the efficacy and safety of psychological interventions for people with neuropathic pain. AUTHORS'
CONCLUSIONS: There is insufficient evidence of the efficacy and safety of psychological interventions for chronic neuropathic pain. The two available studies show no benefit of treatment over either waiting list or placebo control groups.

Entities:  

Mesh:

Year:  2015        PMID: 26513427      PMCID: PMC6485637          DOI: 10.1002/14651858.CD011259.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  64 in total

1.  Randomized trial of cognitive behavior therapy versus supportive psychotherapy for HIV-related peripheral neuropathic pain.

Authors:  Susan Evans; Baruch Fishman; Lisa Spielman; Anabel Haley
Journal:  Psychosomatics       Date:  2003 Jan-Feb       Impact factor: 2.386

2.  An inventory for measuring depression.

Authors:  A T BECK; C H WARD; M MENDELSON; J MOCK; J ERBAUGH
Journal:  Arch Gen Psychiatry       Date:  1961-06

3.  Predictors of attrition in HIV-positive subjects with peripheral neuropathic pain.

Authors:  L Davis; S Evans; B Fishman; A Haley; L A Spielman
Journal:  AIDS Care       Date:  2004-04

4.  A randomized controlled component analysis of a behavioral medicine rehabilitation program for chronic spinal pain: are the effects dependent on gender?

Authors:  I B Jensen; G Bergström; T Ljungquist; L Bodin; A L Nygren
Journal:  Pain       Date:  2001-03       Impact factor: 6.961

5.  The efficacy of a risk factor-based cognitive behavioral intervention and electromyographic biofeedback in patients with acute sciatic pain. An attempt to prevent chronicity.

Authors:  M Hasenbring; H W Ulrich; M Hartmann; D Soyka
Journal:  Spine (Phila Pa 1976)       Date:  1999-12-01       Impact factor: 3.468

6.  Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache.

Authors:  S Morley; C Eccleston; A Williams
Journal:  Pain       Date:  1999-03       Impact factor: 6.961

7.  Is successful rehabilitation of complex regional pain syndrome due to sustained attention to the affected limb? A randomised clinical trial.

Authors:  G Lorimer Moseley
Journal:  Pain       Date:  2005-01-26       Impact factor: 6.961

8.  Therapeutic touch in the treatment of carpal tunnel syndrome.

Authors:  R P Blankfield; C Sulzmann; L G Fradley; A A Tapolyai; S J Zyzanski
Journal:  J Am Board Fam Pract       Date:  2001 Sep-Oct

9.  A confirmatory factor analysis of the Beck Depression Inventory in chronic pain.

Authors:  Stephen Morley; Amanda C de C Williams; Stephanie Black
Journal:  Pain       Date:  2002-09       Impact factor: 6.961

10.  Graded motor imagery is effective for long-standing complex regional pain syndrome: a randomised controlled trial.

Authors:  G L Moseley
Journal:  Pain       Date:  2004-03       Impact factor: 6.961

View more
  27 in total

1.  What Does Cochrane Say about … Non-Pharmacological Treatment of Neuropathic Pain?

Authors: 
Journal:  Physiother Can       Date:  2018       Impact factor: 1.037

2.  Establishing the feasibility, acceptability and preliminary efficacy of a multi-component behavioral intervention to reduce pain and substance use and improve physical performance in older persons living with HIV.

Authors:  Alison A Moore; Jordan E Lake; Suzette Glasner; Arun Karlamangla; Alexis Kuerbis; Diane Preciado; Jessica Jenkins; Blanca X Dominguez; Jury Candelario; Diana H Liao; Lingqi Tang; M Carrington Reid
Journal:  J Subst Abuse Treat       Date:  2019-02-14

3.  Feasibility of a Hybrid Web-Based and In-Person Self-management Intervention Aimed at Preventing Acute to Chronic Pain Transition After Major Lower Extremity Trauma (iPACT-E-Trauma): A Pilot Randomized Controlled Trial.

Authors:  M Bérubé; C Gélinas; N Feeley; G Martorella; J Côté; G Y Laflamme; D M Rouleau; M Choinière
Journal:  Pain Med       Date:  2019-10-01       Impact factor: 3.750

4.  Canada's hidden opioid crisis: the health care system's inability to manage high-dose opioid patients: Fallout from the 2017 Canadian opioid guidelines.

Authors:  Hance Clarke; James Bao; Aliza Weinrib; Ruth E Dubin; Meldon Kahan
Journal:  Can Fam Physician       Date:  2019-09       Impact factor: 3.275

5. 

Authors:  Hance Clarke; James Bao; Aliza Weinrib; Ruth E Dubin; Meldon Kahan
Journal:  Can Fam Physician       Date:  2019-09       Impact factor: 3.275

Review 6.  Neuropathic pain.

Authors:  Luana Colloca; Taylor Ludman; Didier Bouhassira; Ralf Baron; Anthony H Dickenson; David Yarnitsky; Roy Freeman; Andrea Truini; Nadine Attal; Nanna B Finnerup; Christopher Eccleston; Eija Kalso; David L Bennett; Robert H Dworkin; Srinivasa N Raja
Journal:  Nat Rev Dis Primers       Date:  2017-02-16       Impact factor: 52.329

7.  Peoples' experiences of painful diabetic neuropathy: are pain management programmes appropriate?

Authors:  Ben Davies; Fiona Cramp; Jeremy Gauntlett-Gilbert; Candida S McCabe
Journal:  Br J Pain       Date:  2021-01-31

8.  Psychological therapies for the prevention of migraine in adults.

Authors:  Louise Sharpe; Joanne Dudeney; Amanda C de C Williams; Michael Nicholas; Ingrid McPhee; Andrew Baillie; Miriam Welgampola; Brian McGuire
Journal:  Cochrane Database Syst Rev       Date:  2019-07-02

Review 9.  When pain gets stuck: the evolution of pain chronification and treatment resistance.

Authors:  David Borsook; Andrew M Youssef; Laura Simons; Igor Elman; Christopher Eccleston
Journal:  Pain       Date:  2018-12       Impact factor: 7.926

10.  Effects of Mindfulness-Based Cognitive Therapy for Chronic Pain: A Multicenter Study.

Authors:  Estela María Pardos-Gascón; Lucas Narambuena; César Leal-Costa; Antonio Jesús Ramos-Morcillo; María Ruzafa-Martínez; Carlos J van-der Hofstadt Román
Journal:  Int J Environ Res Public Health       Date:  2021-06-29       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.